Article date: November 2012
By: RH Clapp, SM Luckman in Volume 167, Issue 5, pages 1099-1110
BACKGROUND AND PURPOSE Centrally acting histamine H3 receptor ligands are proposed as potential treatments for obesity, although the value of inverse agonists at these receptors is still debated. Functional inhibition of H3 autoreceptors activates neurones in a hypothalamic ‘satiety’ centre. The H3 receptor antagonist, proxyfan was used as a tool to assess the action of histaminergic compounds in this model.
EXPERIMENTAL APPROACH We compared the actions of histamine on feeding with those of an H3 receptor agonist (imetit) and inverse agonist (thioperamide) in rats and mice. Sites of action were identified by immunohistochemistry and the hypothalamic ventromedial nucleus (VMN) was investigated using electrophysiological techniques.
KEY RESULTS Central histamine or thioperamide decreased fast‐induced feeding, whereas imetit increased feeding. Systemic thioperamide entered the brain to activate hypothalamic feeding centres and to reduce feeding without causing any adverse behaviours. Thioperamide activated neurones in the VMN through an action on histamine autoreceptors, whilst imetit had the opposite effect. Proxyfan administered alone did not affect either feeding or electrical activity. However, it blocked the actions of both thioperamide and imetit, acting as a neutral antagonist in this system.
CONCLUSIONS AND IMPLICATIONS The H3 receptor inverse agonist, thioperamide, potently reduced appetite without adverse behavioural effects. This action was blocked by proxyfan, acting as a neutral antagonist in this model and, therefore, this compound is useful in determining the selectivity of H3 receptor‐directed drugs. A major action of thioperamide is through presynaptic autoreceptors, inducing stimulation by endogenous histamine of postsynaptic H1 receptors on anorectic hypothalamic neurones.
DOI: 10.1111/j.1476-5381.2012.02056.x
View this article